Avanos Medical, Inc. (AVNS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: while there is strong growth in some segments and effective cost management, there are significant risks such as tariff impacts, supply chain investments, and declining product lines. The Q&A reveals some uncertainties in future plans and M&A timelines. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
Key Financial Performance
Net Sales $178 million, adjusted for foreign exchange and strategic decisions, organic sales for strategic segments were up 10% year-over-year. The increase was driven by strong growth in Specialty Nutrition Systems and Pain Management and Recovery segments.
Adjusted Diluted Earnings Per Share (EPS) $0.22, reflecting strong sales momentum and effective cost discipline measures.
Adjusted EBITDA $20 million, supported by strong sales and cost management.
Adjusted Gross Margin 52.8%, reflecting effective cost management and sales performance.
Adjusted SG&A as a Percentage of Revenue 40.6%, indicating disciplined cost management.
Specialty Nutrition Systems Organic Growth 14.5% year-over-year, driven by strong demand for enteral feeding products and higher-than-expected distributor orders during the go-direct transition in the UK.
Pain Management and Recovery Organic Sales Growth 2.4% year-over-year, excluding foreign exchange and strategic product withdrawals. Growth was led by double-digit increases in the radiofrequency ablation business.
Operating Profit for Specialty Nutrition Systems 20%, a 130 basis point improvement year-over-year, driven by higher sales volume and partially offset by unfavorable tariff impacts.
Operating Profit for Pain Management and Recovery 3%, a 200 basis point improvement year-over-year, reflecting top-line growth and cost management.
Hyaluronic Acid and Intravenous Infusion Product Lines Declined over 20% year-over-year, primarily due to the divestiture of the HA business.
Free Cash Flow $7 million for the quarter, impacted by higher capital expenditures for strategic supply chain initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Specialty Nutrition Systems (SNS): Achieved double-digit and above-market growth in Q3, driven by strong execution of the commercial team.
Pain Management and Recovery: Posted positive year-over-year growth, led by double-digit growth in the radio frequency ablation business.
CORGRIP tube retention system: Recently launched product designed to reduce tube migration and dislodgement, delivering higher-than-anticipated sales results.
Nexus Medical acquisition: Acquired Nexus Medical, expanding presence in neonatal and pediatric settings and entering a $70 million market. Expected to be immediately accretive to revenue growth and EPS.
International expansion of COOLIEF: Leveraged reimbursement tailwinds in the UK and Japan to grow the COOLIEF offering.
Cost optimization: Identified opportunities to optimize costs without impacting commercial effectiveness, expecting $15-$20 million in annualized cost savings by end of 2026.
Tariff mitigation: Implemented strategies including cost containment, pricing actions, and supply chain investments to mitigate tariff impacts. Exiting China for neonatal syringe production by mid-2026.
Portfolio management: Divested hyaluronic acid business due to low returns and acquired Nexus Medical to enhance growth and profitability.
Game Ready rental transition: Transitioned U.S. rental business to WRS Group to focus on core sports and rehab channels, enhancing profitability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Impact: The company is facing ongoing challenges due to tariffs, particularly on products with country of origin from Mexico and China. This is expected to result in approximately $18 million in incremental manufacturing costs for 2025. The tariff environment remains dynamic, and the company anticipates continued impact into 2026.
Supply Chain Investments: The company is prioritizing supply chain investments to exit China for neonatal syringe production by mid-2026. This will lead to higher-than-anticipated capital expenditures in 2025.
One-Time Charges: The company expects one-time cash charges of approximately $10 million related to cost-saving initiatives, with the majority to be incurred in Q4 2025.
Specialty Nutrition Systems Segment Risks: The company anticipates lower growth in the fourth quarter due to normalization of inventory levels and the absence of one-off tailwinds from the prior year.
Pain Management and Recovery Segment Risks: The surgical pain business is facing delays in the implementation of reimbursement decisions under the NOPAIN Act, which is impacting growth.
Game Ready Portfolio Challenges: The Game Ready portfolio has experienced year-over-year declines, and the company is transitioning the U.S. rental portion of this business to a third party to enhance profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year Revenue Estimates: The company is raising and narrowing its full year revenue estimates to $690 million to $700 million, reflecting strong sales momentum and effective cost discipline measures.
Full Year Adjusted EPS Estimate: The company is raising and narrowing its full year adjusted EPS estimate to $0.85 to $0.95 per share, inclusive of the impact of the hyaluronic acid divestiture and Nexus Medical acquisition.
Cost Improvement Efforts: The company expects to achieve $15 million to $20 million of run rate annualized incremental cost savings by the end of 2026, with onetime cash charges of approximately $10 million, mostly in Q4 2025.
Tariff Mitigation Strategies: The company anticipates the current tariff environment will continue to impact operations in 2026. Strategies include internal cost containment, pricing actions, leveraging temporary tariff exemptions, and lobbying efforts. Supply chain investments are prioritized to exit China for neonatal syringe production by mid-2026.
Capital Expenditures: Slightly higher-than-anticipated capital expenditures in 2025 are expected due to strategic supply chain investments.
Nexus Medical Acquisition: The acquisition is expected to be immediately accretive to both revenue growth and earnings per share, expanding the company's presence in the neonatal and pediatric settings and entering a $70 million market.
Specialty Nutrition Systems Segment: The company anticipates lower but still above-market growth for the NeoMed product line over the next few quarters, with lower year-over-year growth in Q4 due to prior year one-off tailwinds.
Pain Management and Recovery Segment: The company expects sustained growth in the radiofrequency ablation business and progress in the COOLIEF offering internationally, leveraging reimbursement tailwinds in geographies like the UK and Japan.
Free Cash Flow: The company anticipates generating approximately $25 million to $30 million of free cash flow for the year, including onetime charges related to transformation efforts and tariffs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the $15 million to $20 million annualized cost savings plan?
A:The company expects to realize $15 million to $20 million in cost savings by the end of 2026. Efforts include streamlining the organization, reducing senior management, and revamping the R&D organization to improve decision-making and accelerate product development. Most actions are expected to be realized next year.
Q:What can we expect from the product development pipeline as we move into the end of '25 or '26?
A:The company is adopting a hybrid R&D model, combining internal projects with external contracting for certain projects. This approach aims to improve speed to market and focus internal resources on specific projects while outsourcing others to institutions with better capabilities.
Q:What is the company's appetite for more M&A deals, and would you consider larger acquisitions?
A:The company remains focused on synergistic M&A opportunities, particularly in SNS and pain management recovery. They have an appetite for more deals and are actively seeking opportunities, though no specific timeline was provided.
Q:Does the free cash flow assumption of $25 million to $35 million include the $18 million in tariffs and the $10 million one-time cash item from the cost improvement plan?
A:Yes, the free cash flow assumption of $25 million to $30 million for 2025 includes charges related to recent transformation efforts, additional CapEx to accelerate the China exit plan, and aims to reduce the impact of tariffs in 2026.
Q:Review of Unclear Management Responses
A:Management did not provide specific details on the timeline or exact nature of future M&A deals, stating only that they are actively seeking opportunities. Additionally, while discussing the hybrid R&D model, the response lacked clarity on specific projects or timelines for product launches.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Avanos Conference
China
Medical acquisition
NOPAIN Act
Nexus Medical
Nutrition Systems
Pain Recovery
Recovery segment
SNS
Scott
Specialty Nutrition
Systems segment
WRS
ablation
acid divestiture
action
capital expenditure
charge
detail
device
digit market
divestiture HA
divestiture Nexus
estimate
front
goal
imperative
mitigation
point improvement
portion
process
rental
segment basis
strategy tariff
supply chain
tariff environment
AVNS Transcript
Avanos Medical, Inc. (AVNS) Presents at The Citizens Life Sciences Conference 2026 Transcript
Neutral3-11
Avanos Medical, Inc. (AVNS) Q4 2025 Earnings Call Transcript
Positive2-24
The company reported strong financial performance with record high revenue and raised guidance for both revenue and EPS. Despite the divestiture impact, the acquisition of Nexus Medical is accretive, and strategic transitions are underway to mitigate tariff impacts. The Q&A indicates confidence in continued growth and operating leverage, although some management responses lacked clarity. Overall, the sentiment leans positive due to robust financial metrics and optimistic guidance.
Avanos Medical, Inc. (AVNS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Wesdome Gold Mines Ltd. (WDO:CA) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call reveals strong financial performance, including a 57% revenue increase and doubled net income. The company is addressing operational challenges, such as ramp development delays and labor issues, with strategic plans. The Q&A section highlights proactive measures and positive guidance updates, despite some concerns about management's clarity. The opportunistic share repurchase plan and improved cash position further boost sentiment. Overall, the financial health and strategic initiatives suggest a positive stock price movement, though not strongly positive due to ongoing operational risks.
AVNS Slides
AVNS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
